SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY
Clinical trials for SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo aims to shrink tough head and neck cancers
Disease control OngoingThis study tests whether adding an immunotherapy drug (cemiplimab) to low-dose chemotherapy can shrink tumors in people with head and neck cancer that has returned or spread. About 46 adults who have not had prior treatment for advanced disease will receive the combination. The m…
Matched conditions: SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated May 17, 2026 04:41 UTC
-
Virus-Immunotherapy combo targets tough skin cancers
Disease control OngoingThis study tests a two-step treatment for people with rare skin cancers or certain lymphomas that haven't improved with standard care. First, patients receive a virus-based drug (talimogene laherparepvec) injected into tumors to help the immune system recognize and attack cancer …
Matched conditions: SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:47 UTC